Use of antiepileptic drugs in patients with kidney disease

Seminars in Dialysis

Volumn 19, Issue 5, 2006, Pages 408-416

  Lsrani, Rubeen K ^a   Kasbekar, Nishaminy ^a   Haynes, Kevin ^a   Berns, Jeffrey S ^a,b  

^a PENN PRESBYTERIAN MEDICAL CENTER   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT;

ARTICLE; EPILEPSY; HUMAN; KIDNEY DISEASE;

ANTICONVULSANTS; EPILEPSY; HUMANS; KIDNEY DISEASES;

EID: 33748712021     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2006.00195.x     Document Type: Article

References (116)

1. Browne TR: Pharmacokinetics of antiepileptic drugs. Neurology 51:S2-S7, 1998
2. Liponi DF, Winter ME, Tozer TN: Renal function and therapeutic concentrations of phenjtoin. Neurology 34:395-397, 1984
3. Asconape JJ: Some common issues in the use of antiepileptic drugs. Semin Neurol 22:27-39, 2002
4. Dichter MA, Brodie MJ: New antiepileptic drugs. N Engl J Med 334:1583-1590, 1996
5. Section III. Drugs acting on the central nervous system. In: Gilman AG, Hardman JF, Limbird LE (eds). Goodman and Gilman's Pharmacological Basis of Therapeutics, 10th ed. New York: McGraw-Hill, 2005
6. Vanholder R, Van Landschoot N, De Smet R, Schoots A, Ringoir S: Drug protein binding in chronic renal failure, evaluation of nine drugs. Kidney Int 33:996-1004, 1988
7. Fraser DG, Ludden TM, Evens RP, Sutherland EW 3rd: Displacement of phenytoin from plasma binding sites by salicylate. Clin Pharmacol Ther 27:165-169, 1980
8. Dasgupta A, Timmerman TG: In vitro displacement of phenytoin from protein binding by nonsteroidal antiinflammatory drugs tolmetin, ibuprofen, and naproxen in normal and uremic sera. Ther Drug Monit 18:97-99, 1996
9. Peterson GM, Khoo BH, von Witt RJ: Clinical response in epilepsy in relation to total and free serum levels of phenytoin. Ther Drug Monit 13:415-419, 1991
10. Brodie MJ, Dichter MA: Antiepileptic drugs. N Engl J Med 334:168-175, 1996
11. Hachad H, Ragueneau-Majlessi I, Levy RH: New antiepileptic drugs: review on drug interactions. Ther Drug Monit 24:91-103, 2002
12. Johannessen SI, Battino D, Berry DJ, Bialer M, Kramer G, Tomson T, Patsalos PN: Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit 25:347-363, 2003
13. Perucca E, Hebdige S, Frigo GM, Gatti G, Lecchini S, Crema A: Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects. Clin Pharmacol Ther 28:779-789, 1980
14. Patsalos PN, Froscher W, Pisani F, van Rijn CM: The importance of drug interactions in epilepsy therapy. Epilepsia 43:365-385, 2002
15. Giaccone M, Bartoli A, Gatti G, Marchiselli R, Pisani F, Latella MA, Perucca E: Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. Br J Clin Pharmacol 41:575-579, 1996
16. Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure 13(suppl 1):S5-S9, 2004; discussion S10
17. Roberts WL, De BK, Coleman JP, Annesley TM: Falsely increased immunoassay measurements of total and unbound phenytoin in critically ill uremic patients receiving fosphenytoin. Clin Chem 45:829-837, 1999
18. Annesley TM, Kurzyniec S, Nordblom GD, Buchanan N, Pool W, Reily M, Talaat R, Roberts WL: Olucuronidation of prodrag reactive site: isolation and characterization of oxymethylglucuronide metabolite of fosphenytoin. Clin Chem 47:910-918, 2001
19. Frenchie D, Bastani B: Significant removal of phenytoin during high flux dialysis with cellulose triacetate dialyzer. Nephrol Dial Transplant 13:817-818, 1998
20. Martin E, Gambertoglio JG, Adler DS, Tozer TN, Roman LA, Grausz H: Removal of phenytoin by hemodialysis in uremic patients. JAMA 238:1750-1753, 1977
21. Matson JR, Krous HF, Blackstock R: Diphenylhydantoin-induced hyper-sensitivity reaction with interstitial nephritis. Hum Pathol 16:94-97, 1985
22. Hyman LR, Ballow M, Knieser MR: Diphenylhydantoin interstitial nephritis. Roles of cellular and humoral immunologic injury. J Pediatr 92:915-920, 1978
23. Fichman MP, Kleeman CR, Bethune JE: Inhibition of antidiuretic hormone secretion by diphenylhydantoin. Arch Neurol 22:45-53, 1970
24. Sordillo P, Sagransky DM, Mercado RM, Michelis MF: Carbamazepine-induced syndrome of inappropriate antidiuretic hormone secretion. Reversal by concomitant phenytoin therapy. Arch Intern Med 138:299-301, 1978
25. Guzek JW, Russell JT, Thorn NA: Inhibition of diphenylhydantoin of vasopressin release from isolated rat neurohypophyses. Acta Pharmacol Toxicol 34:1-4, 1974
26. McBryde KD, Wilcox J, Kher KK: Hyperphosphatemia due to fosphenytoin in a pediatric ESRD patient. Pediatr Nephrol 20:1182-1185, 2005
27. Tapolyai M, Campbell M, Dailey K, Udvari-Nagy S: Hemodialysis is as effective as hemoperfusion for drug removal in carbamazepine poisoning. Nephron 90:213-215, 2002
28. Kielstein JT, Schwarz A, Arnavaz A, Sehlberg O, Emrich HM, Fliser D: High-flux hemodialysis - an effective alternative to hemoperfusion in the treatment of carbamazepine intoxication. Clin Nephrol 57:484-486, 2002
29. Schuerer DJ, Brophy PD, Maxvold NJ, Kudelka T, Bunchman TE: High-efficiency dialysis for carbamazepine overdose. J Toxicol Clin Toxicol 38:321-323, 2000
30. Chetty M, Sarkar P, Aggarwal A, Sakhuja V: Carbamazepine poisoning: treatment with haemodialysis. Nephrol Dial Transplant 18:220-221, 2003
31. Lee CS, Wang LH, Marbury TC, Bruni J, Perchalski RJ: Hemodialysis clearance and total body elimination of carbamazepine during chronic hemodialysis. Clin Toxicol 17:429-438, 1980
32. Patsalos PN, Perucca E: Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2:347-356, 2003
33. Eijgenraam JW, Buurke EJ, van der Laan JS: Carbamazepine-associated acute tubulointerstitial nephritis. Neth J Med 50:25-28, 1997
34. Hegarty J, Picton M, Agarwal G, Pramanik A, Kalra PA: Carbamazepine-induced acute granulomatous interstitial nephritis. Clin Nephrol 57:310-313, 2002
35. Van Amelsvoort T, Bakshi R, Devaux CB, Schwabe S: Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia 35:181-188, 1994
36. Kimura T, Matsui K, Sato T, Yoshinaga K: Mechanism of carbamazepine (Tegretol)-induced antidiuresis: evidence for release of antidiuretic hormone and impaired excretion of a water load. J Clin Endocrinol Metab 38:356-362, 1974
37. Meinders AE, Cejka V, Robertson GL: The antidiuretic action of carbamazepine in man. Clin Sci Mol Med 47:289-299, 1974
38. Sachdeo RC, Wasserstein A, Mesenbrink PJ, D'Souza J: Effects of oxcarbazepine on sodium concentration and water handling. Ann Neurol 51:613-620, 2002
39. Thomas TH, Ball SO, Wales JK, Lee MR: Effect of carbamazepine on plasma and urine arginine-vasopressin. Clin Sci Mol Med 54:419-424, 1978
40. Gold PW, Robertson GL, Ballenger JC, Kaye W, Chen J, Rubinow DR, Goodwin FK, Post RM: Carbamazepine diminishes the sensitivity of the plasma arginine vasopressin response to osmotic stimulation. J Clin Endocrinol Metab 57:952-957, 1983
41. Dasgupta A, Jacques M, Malhotra D: Diminished protein binding capacity of uremic sera for valproate following hemodialysis : role of free fatty acids and uremic compounds. Am J Nephrol 16:327-333, 1996
42. Kandrotas RJ, Love JM, Gal P, Oles K.S: The effect of hemodialysis and hemoperfusion on serum valproic acid concentration. Neurology 40:1456-1458, 1990
43. Kielstein JT, Woywodt A, Schumann G, Haller H, Fliser D: Efficiency of high-flux hemodialysis in the treatment of valproic acid intoxication. J Toxicol Clin Toxicol 41:873-876, 2003
44. Kane SL, Constantiner M, Staubus AE, Meinecke CD, Sedor JR: High-flux hemodialysis without hemoperfusion is effective in acute valproic acid overdose. Ann Pharmacother 34:1146-1151, 2000
45. Lin CY, Chiang H: Sodium-valproate-induced interstitial nephritis. Nephren 48:43-46, 1988
46. Yoshikawa H, Watanabe T, Abe T: Tubulo-interstitial nephritis caused by sodium valproate. Brain Dev 24:102-105, 2002
47. Knorr M, Schaper J, Harjes M, Mayatepek E, Rosenbaum T: Fanconi syndrome caused by antiepileptic therapy with valproic acid. Epilepsia 45:868-871, 2004
48. Branten AJ, Wetzels JF, Weber AM, Koene RA: Hyponatremia due to sodium valproate. Ann Neurol 43:265-267, 1998
49. Pugh CB: Phenytoin and phenobarbital protein binding alterations in a uremic burn patient. Drug Intell Clin Pharm 21:264-267, 1987
50. Chapter 12. Use of dialysis and hemoperfusion in treatment of poisoning. In: Daugirdas JT, Blake PG, Ing TS (eds). Handbook of Dialysis, 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2001:263-277
51. Zawada ET Jr, Nappi J, Done G, Rollins D: Advances in the hemodialysis management of phenobarbital overdose. South Med J 76:6-8, 1983
52. Streete JM, Berry DJ, Jones JA, Groggin MJ: Clearance of phenylethylmalonamide during haemodialysis of a patient with renal failure. Ther Drug Monit 12:281-283, 1990
53. Palmer BF: Effectiveness of hemodialysis in the extracorporeal therapy of phenobarbital overdose. Am J Kidney Dis 36:640-643, 2000
54. Porto I, John EG, Heilliczer J: Removal of phenobarbital during continuous cycling peritoneal dialysis in a child. Pharmacotherapy 17:832-835, 1997
55. Marquardt ED, Ishisaka DY, Batra KK, Chin B: Removal of ethosuximide and phenobarbital by peritoneal dialysis in a child. Clin Pharm 11:1030-1031, 1992
56. Keller E: Peritoneal kinetics of different drugs. Clin Nephrol 30(suppl 1):S24-S28, 1988
57. Wallace SJ: Use of ethosuximide and valproate in the treatment of epilepsy. Neurol Clin 4:601-616, 1986
58. Goulet JR, Kinkel AW, Smith TC: Metabolism of ethosuximide. Clin Pharmacol Ther 20:213-218, 1976
59. Buchanan RA, Kinkel AW, Smith TC: The absorption and excretion of ethosuximide. Int J Clin Pharmacol 7:213-218, 1973
60. Bachmann K, He Y, Sarver JG, Peng N: Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes. Xenobiotica 33:265-276, 2003
61. Salke-Kellermann RA, May T, Boenigk HE: Influence of ethosuximide on valproic acid serum concentrations. Epilepsy Res 26:345-349, 1997
62. Rowan AJ, Meijer TW, de Beer-Pawlikowski N, van der Geest P, Meinardi H: Valproate-ethoBuximide combination therapy for refractory absence seizures. Arch Neurol 40:797-802, 1983
63. Marbury TC, Lee CS, Perchalski RJ, Wilder BJ: Hemodialysis clearance of ethosuximide in patients with chronic renal disease. Am J Hosp Pharm 38:1757-1760, 1981
64. Casteels K, Van Geet C, Wouters K: Ethosuximide-associated lupus with cerebral and renal manifestations. Ear J Pediatr 157:780, 1998
65. Takeda S, Koizumi F, Takazakura E: Ethosuximide-induced lupus-like syndrome with renal involvement. Intern Med 35:587-591, 1996
66. Teoh PC, Chan HL: Lupus-scleroderma syndrome induced by ethosuximide. Arch Dis Child 50:658-661, 1975
67. Mattson RH, Cramer JA, Collins JF, Smith DB, Delgado-Escueta AV, Browne TR, Williamson PD, Treiman DM, McNamara JO, McCutchen CB, et al.: Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 313:145-151, 1985
68. Heipertz R, Guthoff A, Bernhardt W: Primidone metabolism in renal insufficiency and acute intoxication. J Neurol 221:101-104, 1979
69. Lee CS, Marbury TC, Perchalski RT, Wilder BJ: Pharmacokinetics of primidone elimination by uremic patients. J Clin Pharmacol 22:301-308, 1982
70. Bruni J, Albright PS : The clinical pharmacology of antiepileptic drugs. Clin Neuropharmacol 7:1-34, 1984
71. Lehmann DF: Primidone crystalluria following overdose. A report of a case and an analysis of the literature. Med Toxicol Adverse Drug Exp 2:383-387, 1987
72. Fogazzi GB: Crystalluria: a neglected aspect of urinary sediment analysis. Nephrol Dial Transplant 11:379-387, 1996
73. van Heijst AN, de Jong W, Seldenrijk R, van Dijk A: Coma and crystalluria: a massive primidone intoxication treated with haemoperfusion. J Toxicol Clin Toxicol 20:307-318, 1983
74. Dougherty JA, Rhoney DH: Gabapentin: a unique anti-epileptic agent. Neurol Res 23:821-829, 2001
75. French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stem J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ Jr, Turk WR, Fischer JH, Bourgeois B, Wilner A, Faught RE Jr, Sachdeo RC, Beydoun A, Glauser TA, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology; Quality Standards Subcommittee of the American Academy of Neurology; American Epilepsy Society: Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 62:1252-1260, 2004
76. Vollmer KO, von Hodenberg A, Kolle EU: Pharmacokinetics and metabolism of gabapentin in rat, dog and man. Arzneimittelforschung 36:830-839, 1986
77. Blum RA, Comstock TJ, Sica DA, Schultz RW, Keller E, Reetze P, Bockbrader H, Tuerck D, Busch JA, Reece PA, et al.: Pharmacokinetics of gabapentin in subjects with various degrees of renal function. Clin Pharmacol Ther 56:154-159, 1994
78. Gabapentin (Neurontin) package insert. Morris Plains, NJ: Parke-Davis, 2002
79. Wong MO, Eldon MA, Keane WF, Turck D, Bockbrader HN, Underwood BA, Sedman AJ, Halstenson CE: Disposition of gabapentin in anuric subjects on hemodialysis. J Clin Pharmacol 35:622-626, 1995
80. Btaiche IF, Woster PS: Gabapentin and lamotrigine: novel antiepileptic drugs. Am J Health Syst Pharm 52:61-69, 1995
81. Hovinga CA: Levetiracetam: a novel antiepileptic drug. Pharmacotherapy 21:1375-1388, 2001
82. Glauser TA, Pellock JM, Bebin EM, Fountain NB, Ritter FJ, Jensen CM, Shields WD: Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epllepsia 43:518-524, 2002
83. Sisodiya SM, Sander JW, Patsalos PN: Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction. Epilepsy Res 48:217-219, 2002
84. Patsalos PN: Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 85:77-85, 2000
85. Patsalos PN: Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 43:707-724, 2004
86. Rosenfeld WE: Topiramate: a review of preclinical, pharmacokinetic, and clinical data. Clin Ther 19:1294-1308, 1997
87. Perucca E: A pharmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacol Res 35:241-256, 1997
88. Britzi M, Perucca E, Soback S, Levy RH, Fattore C, Crema F, Gatti G, Doose DR, Maryanoff BE, Bialer M: Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. Epilepsia 46:378-384, 2005
89. Sachdeo RC, Sachdeo SK, Levy RH, Streeter AJ, Bishop FE, Kunze KL, Mather GG, Roskos LK, Shen DD, Thummel KE, Trager WF, Curtin CR, Doose DR, Gisclon LG, Bialer M: Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. Epilepsia 43:691-696, 2002
90. Markind JE: Topiramate: a new antiepileptic drug. Am J Health Syst Pharm 55:554-562, 1998
91. Stowe CD, Bollinger T, James LP, Haley TM, Griebel ML, Farrar HC 3rd: Acute mental status changes and hyperchloremic metabolic acidosis with long-term topiramate therapy. Pharmacotherapy 20:105-109, 2000
92. Shank RP, Gardocki JF, Vaught JL, Davis CB, Schupsky JJ, Raffa RB, Dodgson SJ, Nortey SO, Maryanoff BE: Topiramate: preclinical evaluation of structurally novel anticonvulsant. Epilepsia 35:450-460, 1994
93. Wilner A, Raymond K, Pollard R: Topiramate and metabolic acidosis. Epilepsia 40:792-795, 1999
94. Wasserstein AG, Rak I, Reife RA: Nephrolithiasis during treatment with topiramate [abstract], Epilepsia 36(suppl 3):S153, 1995
95. Faught E: Review of United States and European clinical trials of zonisamide in the treatment of refractory partial-onset seizures. Seizure 135:859-865, 2004
96. Kochak GM, Page JG, Buchanan RA, Peters R, Padgett CS: Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures. J Clin Pharmacol 38:166-171, 1998
97. Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure 13(suppl 1):S5-S9, 2004
98. Ijiri Y, Inoue T, Fukuda F, Suzuki K, Kobayashi T, Shibaharu N, Takenaka H, Tanaka K: Dialyzability of the antiepileptic drug zonisamide in patients undergoing hemodialysis. Epilepsia 45:924-927, 2004
99. Elwes RD, Binnie CD: Clinical pharmacokinetics of newer antiepileptic drugs. Lamotrigine, vigabatrin, gabapentin and oxcarbazepine. Clin Pharmacokinet 30:403-415, 1996
100. Schmidt D, Elger CE: What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behav 5:627-635, 2004
101. Baruzzi A, Albani F, Riva R: Oxcarbazepine: pharmacokinetic interactions and their clinical relevance. Epilepsia 35(suppl 3):S14-S19, 1994
102. Lloyd P, Flesch G, Dieterle W: Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 35(suppl 3):S10-S13, 1994
103. Rouan MC, Lecaillon JB, Godbillon J, Menard F, Darragon T, Meyer P, Kourilsky O, Hillion D, Aldigier JC, Jungers P: The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites. Eur J Clin Pharmacol 47:161-167, 1994
104. Graves NM: Felbamate. Ann Pharmacother 27:1073-1081, 1993
105. Leppik IE: Felbamate. Epilepsia 36(suppl 2):S66-S72, 1995
106. Glue P, Sulowicz W, Colucci R, Banfleld C, Pai S, Lin C, Affrime MB: Single-dose pharmacokinetics of felbamate in patients with renal dysfunction. Br J Clin Pharmacol 44:91-93, 1997
107. Sparagana SP, Strand WR, Adams RC: Felbamate urolithiasis. Epilepsia 42:682-685, 2001
108. Garnett WR: Lamotrigine: pharmacokinetics. J Child Neurol 12(suppl 1):S10-S15, 1997
109. Goa KL, Ross SR, Chrisp P: Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 46:152-176, 1993
110. Wootton R, Soul-Lawton J, Rolan PE, Sheung CT, Cooper JD, Posner J: Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers. Br J Clin Pharmacol 43:23-27, 1997
111. Fillastre JP, Taburet AM, Fialaire A, Etienne I, Bidault R, Singlas E: Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis. Drugs Exp Clin Res 19:25-32, 1993
112. Brodie MJ: Lamotrigine - an update. Can J Neurol Sci 23:S6-S9, 1996
113. Fervenza FC, Kanakiriya S, Kunau RT, Gibney R, Lager DJ: Acute granulomatous interstitial nephritis and colitis in anticonvulsant hypersensitivity syndrome associated with lamotrigine treatment. Am J Kidney Dis 36:1034-1040, 2000
114. Adkins JC, Noble S: Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy. Drugs 55:437-460, 1998
115. So EL, Wolff D, Graves NM, Leppik IE, Cascino GD, Pixton GC, Gustavson LE: Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing antiepilepsy drugs. Epilepsy Res 22:221-226, 1995
116. Cato A 3rd, Gustavson LE, Qian J, El-Shourbagy T, Kelly EA. Effect of renal impairment on the pharmacokinetics and tolerability of tiagabine. Epilepsia 39:43-47, 1998